Optometric Physician



Vol. 24, #2 •   Monday, January 9, 2023


Off the Cuff: TQ ReQueue

In March 2021, Dr. Epstein wrote an editorial titled “The End of an Era.” Tyler Thompson, Tyler Quarterly’s (TQ) founder and editor, announced his retirement and the end of this essential contact lens publication after 38 years. TQ was indispensable for not only clinical practice but for contact lens education as well. This quarterly publication kept us up to date on lens options, parameters, and materials. It also had information about contact lens cleaners and solutions as well as kept us apprised of contact lens discontinuations, smaller lab lens options, and transfers of brand ownerships with the ever-merging contact lens companies. Inside the back cover was the radius of curvature to diopter conversion chart godsend that I used regularly as a student. Who am I kidding? I still can’t think in radius.

I am exceptionally pleased to announce TQ is back. In fact, it wasn’t even gone all that long. Six months after it was announced that the last issue was published in March 2021, a new owner was found and publishing restarted in September 2021. Some of you may have already known this, but I, for one, did not. Between the announcement of its last issue, the pandemic, and life in general keeping my focus elsewhere, it never occurred to me to even consider looking for it.

Just last week, a manila envelope addressed to Dr. Epstein made its way onto my desk. Inside was a letter dated August 2022 detailing TQ’s return and asking for a mention to the Optometric Physician audience. This letter was paperclipped to the most recent copy of TQ. Holding it in my hands felt like coming home. I have tremendous gratitude for TQ’s new owner for reviving this mainstay of optometric practice and wish them many years of publication success.


Shannon L. Steinhäuser, OD, MS, FAAO
Chief Medical Editor


Want to share your perspective?
Write to Dr. Shannon L. Steinhäuser, OD, MS, FAAO at ssteinhauser@gmail.com. The views expressed in this editorial are solely those of the author and do not necessarily represent the opinions of Jobson Medical Information LLC (JMI), or any other entities or individuals.


Papillary and Peripapillary Hemorrhages in Eyes With Pathologic Myopia

In this study, 2171 patients with pathologic myopia (3774 eyes) were examined to determine the prevalence, characteristics, and causes of papillary and peripapillary hemorrhages (PPHs) in eyes with pathologic myopia (PM). PM patients were retrospectively studied between 2011 and 2018. Fundus images were used to diagnose and classify the PPHs. Fundus fluorescein angiographic (FFA) and optical coherence tomographic (OCT) images were used to determine the status of the retinal vessels and tissue at and around the PPH sites. Visual field data determined by Goldmann perimetry and Humphrey visual field analyzer were also analyzed.

Eighty-eight patients (97 eyes) had PPHs; mean axial length for a prevalence of 4.05%. Thirty eyes (30.9%) recurred. Among the 90 eyes with a single-site PPH, the most common type and location were the conus type and the temporal side, respectively. Regression analysis showed that patchy atrophy reduced the risk of recurrences more than diffuse atrophy, whereas a longer axial length and potential glaucoma increased the risk. FFA and OCT showed that PPHs developed in the area of straightened retinal arterioles, at or beside the peak of a ridge, in an area of compressed retinal tissue.

Researchers concluded that PPHs were present in 4.05% of PM eyes and were most often located in the temporal peripapillary atrophic region of the retina. Axial elongation, mild myopic maculopathy, and potential glaucoma were risk factors for recurrences.

SOURCE: Xiong J, Du R, Xie S, et al. Papillary and peripapillary hemorrhages in eyes with pathologic myopia. Invest Ophthalmol Vis Sci. 2022;63(12):28.



Chronic Kidney Disease and its Association with Cataracts

The authors of this study explored the association between chronic kidney disease (CKD) and cataracts. A total of 121,380 participants collected from 29 community-based recruitment centers since 2008 were analyzed. The association between CKD and self-reported diagnosed cataracts was examined in a cross-sectional cohort and was validated in a longitudinal cohort of 25,263 participants without cataracts at baseline.

Multivariate logistic regression showed that CKD was significantly associated with a higher prevalence of self-reported diagnosed cataracts. In the validation cohort, a higher incidence of cataracts was also noted in the CKD group compared to the non-CKD group during a mean 47-month follow-up. After adjusting for confounders, subjects with CKD had a 1.498-fold higher risk of incident cataracts than those without CKD.

The authors found that CKD was associated with a higher prevalence of cataracts.

SOURCE: Huang CY, Lee JI, Chang CW, et al. Chronic kidney disease and its association with cataracts-A cross-sectional and longitudinal study. Front Public Health. 2022;10:1029962.

Formaldehyde Release From Eyelash Glues: Analysis Using the Chromotropic Acid Method

Popularity of eyelash enhancements has increased dramatically. Eyelash enhancements are available as an over-the-counter consumer product with glue included and as a professional product where proprietary glues are typically used. Both types of eyelash extension glues may release formaldehyde despite not being declared as an ingredient. Although formaldehyde is a carcinogen and may cause allergic contact dermatitis, few studies have assessed its presence in eyelash glues. The aim of the study was to evaluate professional and consumer eyelash glues for the presence of formaldehyde using the chromotropic acid method (CAM).

A total of 37 eyelash glues were evaluated: 17 consumer eyelash glues (2 of which declared formaldehyde) and 20 professional eyelash glues (none of which declared formaldehyde) were purchased and analyzed with the CAM of testing. For consumer eyelash glues, the 2 glues that declared formaldehyde were positive on CAM testing as well as 2 glues that did not declare formaldehyde. Of the 20 professional eyelash glues, 75.0% were positive for formaldehyde.

This study demonstrated that some consumer eyelash glues and most professional eyelash glues released formaldehyde when evaluated with CAM. Patients and clinicians should be aware that both consumer and professional eyelash glues can be sources of formaldehyde.

SOURCE: Xiong M, Shaik JA, Hylwa S. Formaldehyde release from eyelash glues: analysis using the chromotropic acid method. Dermatitis. 2022;33(6):442-446.



Industry News


• STAAR Surgical Company announced its board of directors appointed Thomas G. Frinzi, board chair of STAAR, to serve as president and CEO, upon the retirement of President and Chief Executive Officer Caren Mason December 31. Read more.
• Nancy M. Mackowsky, OD, FCOVD, FNORA, was appointed chair of the Neuro-Optometric Rehabilitation Association, International (NORA) Fellowship Committee, succeeding Derrick Tong, OD, FAAO, FCOVD, FNORA, who will be stepping down from the position February 1. Read more.

Prevent Blindness Issues Call for Nominations, Offers Glaucoma Resources

Prevent Blindness announced a the call for nominations for the 2023 Jenny Pomeroy Award for Excellence in Vision and Public Health, and the fourth annual Rising Visionary Award. Learn more.
As part of January’s National Glaucoma Awareness Month, the group is offering a variety of resources for glaucoma patients and their caregivers. Learn more.














Journal Reviews Editor:
Katherine M. Mastrota, MS, OD, EMBA, FAAO

Optometric Physician™ (OP) newsletter is owned and published by Dr. Arthur Epstein. It is distributed by the Review Group, a Division of Jobson Medical Information LLC (JMI), 19 Campus Boulevard, Newtown Square, PA 19073.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add Optometricphysician@jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Optometric Physician. HOW TO SUBMIT NEWS E-mail optometricphysician@jobson.com or FAX your news to: 610.492.1039.

Advertising: For information on advertising in this e-mail newsletter, please contact sales managers Michael Hoster, Michele Barrett or Jonathan Dardine.

News: To submit news or contact the editor, send an e-mail, or FAX your news to 610.492.1039